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Introduction
The transcription factor Retinoid X Receptor (RXR) is a member of nuclear receptor superfamily and has an unusually complicated biology. In fact, the precise molecular mechanisms used by RXR to interact with the genome and to regulate gene expression are still not known (Daniel et al., 2014) . Regardless of the mechanisms, however, silent or ligand activated RXR (including activation through permissive heterodimerization with other nuclear receptors) together with a network of RXR enhancers, are involved in the development of phenotypes that can be disease associated. Through RXR activation, these phenotypes can be influenced by synthetic small molecule RXR receptor specific agonists (Table 1) .
The role of activated RXR through LXR/RXR and RXR/PPARγ permissive heterodimers in in vivo and in vitro models of Alzheimer's disease (AD) was first demonstrated a decade ago using partially specific LXR or PPARγ agonists (Heneka et al., 2005; Koldamova et al., 2003; Koldamova et al., 2005) and later confirmed in numerous studies (Koldamova et al., 2014a) . A promising therapeutic effect of a synthetic small molecule and specific RXR agonist -bexarotene, in AD model mice has only been recently reported (Cramer et al., 2012) . Other laboratories failed to reproduce the beneficial effect of bexarotene on amyloid plaques (Fitz et al., 2013; Price et al., 2013; Tesseur et al., 2013; Veeraraghavalu et al., 2013) . Fitz et al., however, reported a significant decrease in soluble Aβ species, including Aβ oligomers by 50%, following bexarotene treatment of APP/PS1 mice (Fitz et al., 2013 
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